---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278425728.md"
description: "Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden."
datetime: "2026-03-09T16:33:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278425728.md)
  - [en](https://longbridge.com/en/news/278425728.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278425728.md)
generator: "portal-rs"
---

# 

Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden.

### Related Stocks

- [BNTC.US](https://longbridge.com/en/quote/BNTC.US.md)

## Related News & Research

- [Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/296672427.md)
- [Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright](https://longbridge.com/en/news/278425413.md)
- [Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/294018130.md)
- [Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia](https://longbridge.com/en/news/286499271.md)
- [Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50-Day Moving Average   - Time to Sell?](https://longbridge.com/en/news/296312501.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**